GB9221220D0
(en)
*
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
ES2295093T3
(es)
|
1993-04-23 |
2008-04-16 |
Wyeth |
Conjugados y anticuerpos de rapamicina.
|
US7279561B1
(en)
*
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US7063857B1
(en)
|
1999-04-30 |
2006-06-20 |
Sucampo Ag |
Use of macrolide compounds for the treatment of dry eye
|
DE60010098T2
(de)
|
1999-08-24 |
2005-03-31 |
Ariad Gene Therapeutics, Inc., Cambridge |
28-epirapaloge
|
AU769315B2
(en)
|
1999-08-24 |
2004-01-22 |
Cellgate, Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
US6790228B2
(en)
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US20050002986A1
(en)
*
|
2000-05-12 |
2005-01-06 |
Robert Falotico |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6776796B2
(en)
*
|
2000-05-12 |
2004-08-17 |
Cordis Corportation |
Antiinflammatory drug and delivery device
|
US7300662B2
(en)
*
|
2000-05-12 |
2007-11-27 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
CA2424029C
(en)
|
2000-09-29 |
2008-01-29 |
Cordis Corporation |
Coated medical devices
|
US20040241211A9
(en)
*
|
2000-11-06 |
2004-12-02 |
Fischell Robert E. |
Devices and methods for reducing scar tissue formation
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
US6534693B2
(en)
*
|
2000-11-06 |
2003-03-18 |
Afmedica, Inc. |
Surgically implanted devices having reduced scar tissue formation
|
NZ526708A
(en)
*
|
2000-11-28 |
2005-07-29 |
Wyeth Corp |
Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2005201004A1
(en)
*
|
2001-02-19 |
2005-03-24 |
Novartis Ag |
Cancer treatment
|
PT3351246T
(pt)
|
2001-02-19 |
2019-06-07 |
Novartis Pharma Ag |
Derivado de rapamicina para o tratamento de um tumor sólido associado a angiogenese desregulada
|
AU2011226833B9
(en)
*
|
2001-02-19 |
2014-07-03 |
Novartis Ag |
Cancer treatment
|
AU2016206379B2
(en)
*
|
2001-02-19 |
2017-09-14 |
Novartis Ag |
Cancer Treatment
|
US7682387B2
(en)
*
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US20050070468A1
(en)
*
|
2001-11-21 |
2005-03-31 |
Sucampo Ag |
Use of fk506 and analogues for treating allergic diseases
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
AU2003230985A1
(en)
*
|
2002-04-18 |
2003-11-03 |
Stephen H. Embury |
Method and composition for preventing pain in sickle cell patients
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EP1944026B1
(en)
|
2002-05-16 |
2013-06-26 |
Novartis AG |
Use of EDG receptor binding agents in cancer
|
JP4265888B2
(ja)
*
|
2002-06-12 |
2009-05-20 |
株式会社リコー |
画像形成装置
|
DE60315723T2
(de)
|
2002-07-16 |
2008-06-19 |
Biotica Technology Ltd. |
Herstellung von Polyketiden und anderen natürlichen Produkten
|
MXPA05003254A
(es)
|
2002-09-24 |
2005-06-08 |
Novartis Ag |
Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
|
AU2003293529A1
(en)
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
JP2006516548A
(ja)
|
2002-12-30 |
2006-07-06 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
迅速ゲル化ポリマー組成物からの薬物送達法
|
CA2526617C
(en)
|
2003-05-20 |
2015-04-28 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
AU2004274026A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
US7780973B2
(en)
*
|
2003-12-15 |
2010-08-24 |
Ethicon Endo-Surgery, Inc. |
Method and device for minimally invasive implantation of biomaterial
|
US20050142161A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Freeman Lynetta J. |
Collagen matrix for soft tissue augmentation
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US8021849B2
(en)
*
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
KR101387456B1
(ko)
|
2005-02-09 |
2014-04-21 |
산텐 세이야꾸 가부시키가이샤 |
질환 또는 상태의 치료를 위한 액체 제제
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
KR20070116868A
(ko)
|
2005-03-11 |
2007-12-11 |
바이오티카 테크놀로지 리미티드 |
39데스메톡시라파마이신 및 그 유사체의 의학적 용도
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
US7189582B2
(en)
*
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
KR20130087058A
(ko)
|
2005-07-20 |
2013-08-05 |
노파르티스 아게 |
피리미딜아미노벤즈아미드와 mtor 키나제 억제제의 조합물
|
DK1912675T3
(en)
|
2005-07-25 |
2014-03-24 |
Emergent Product Dev Seattle |
B-cell reduction using specific and cd37-cd20-specific binding molecules
|
JP5164167B2
(ja)
|
2005-08-30 |
2013-03-13 |
ユニバーシティー オブ マイアミ |
免疫調節性腫瘍壊死因子受容体25(tnfr25)のアゴニスト、アンタゴニスト及び免疫毒素
|
EP2001438A2
(en)
|
2006-02-09 |
2008-12-17 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
DK2001466T3
(en)
|
2006-03-23 |
2016-02-29 |
Santen Pharmaceutical Co Ltd |
LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
US7883855B2
(en)
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080097591A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080103584A1
(en)
*
|
2006-10-25 |
2008-05-01 |
Biosensors International Group |
Temporal Intraluminal Stent, Methods of Making and Using
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
WO2008083239A2
(en)
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for stimulating an immune response
|
WO2008082984A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Non-denaturing lysis reagent for use with capture-in-solution immunoassay
|
WO2008082979A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Diagnostic test for the detection of a molecule or drug in whole blood
|
CA2673296C
(en)
|
2006-12-29 |
2012-10-16 |
Abbott Laboratories |
Improved assay for immunosuppressant drugs
|
US7914999B2
(en)
|
2006-12-29 |
2011-03-29 |
Abbott Laboratories |
Non-denaturing lysis reagent
|
US20080265343A1
(en)
*
|
2007-04-26 |
2008-10-30 |
International Business Machines Corporation |
Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
EP2245165A4
(en)
|
2008-01-11 |
2011-06-01 |
Massachusetts Eye & Ear Infirm |
TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
|
US20100048912A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
ES2368700T3
(es)
|
2008-04-11 |
2011-11-21 |
Emergent Product Development Seattle, Llc |
Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
|
EP3011958A1
(en)
|
2008-06-20 |
2016-04-27 |
Novartis AG |
Paediatric compositions for treating multiple sclerosis
|
DK2365802T3
(da)
|
2008-11-11 |
2017-11-13 |
Univ Texas |
Mikrokapsler af rapamycin og anvendelse til behandling af cancer
|
US20110312916A1
(en)
|
2009-02-05 |
2011-12-22 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
CN101924315B
(zh)
*
|
2009-06-16 |
2014-09-03 |
德昌电机(深圳)有限公司 |
换向器及其制造方法
|
CA2806840C
(en)
|
2009-08-03 |
2019-08-27 |
Eckhard R. Podack |
Method for in vivo expansion of t regulatory cells
|
WO2011026122A2
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
JP5918214B2
(ja)
|
2010-04-13 |
2016-05-18 |
ノバルティス アーゲー |
がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ
|
NZ602807A
(en)
|
2010-04-16 |
2014-02-28 |
Novartis Ag |
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2012112847A1
(en)
|
2011-02-18 |
2012-08-23 |
Novartis Pharma Ag |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6086902B2
(ja)
|
2011-04-25 |
2017-03-01 |
ノバルティス アーゲー |
ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤およびmTOR阻害剤の組み合わせ
|
EP2589383A1
(en)
|
2011-11-06 |
2013-05-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
FKBP subtype-specific rapamycin analogue for use in treatment of diseases
|
KR20140091695A
(ko)
|
2011-11-15 |
2014-07-22 |
노파르티스 아게 |
포스포이노시티드 3-키나제 억제제와 야누스 키나제 2-신호 전달자 및 전사 활성화제 5 경로의 조절제의 조합물
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
JP6378170B2
(ja)
|
2012-04-12 |
2018-08-22 |
イェール ユニバーシティーYale University |
異なる医薬品の制御送達のためのビヒクル
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
EP2906214A1
(en)
|
2012-10-12 |
2015-08-19 |
The Board of Regents of The University of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
KR20150136047A
(ko)
|
2013-01-09 |
2015-12-04 |
유니버시티 오브 마이애미 |
TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
SG11201507093WA
(en)
|
2013-03-14 |
2015-10-29 |
Univ Maryland Baltimore Office Of Technology Transfer |
Androgen receptor down-regulating agents and uses thereof
|
AU2014265142A1
(en)
|
2013-05-17 |
2015-12-24 |
Medimmune, Llc |
Receptors for B7-H4
|
US9593356B2
(en)
|
2013-06-11 |
2017-03-14 |
Takara Bio Usa, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
RU2016104643A
(ru)
|
2013-08-12 |
2017-09-19 |
Токай Фармасьютикалз, Инк. |
Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
|
US9580758B2
(en)
|
2013-11-12 |
2017-02-28 |
Luc Montagnier |
System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
CA3206208A1
(en)
|
2013-12-31 |
2015-07-09 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
EP3104890A1
(en)
|
2014-02-11 |
2016-12-21 |
Novartis AG |
Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
IL293603B2
(en)
|
2014-04-07 |
2024-03-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
CA2968049A1
(en)
|
2014-04-16 |
2015-10-22 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
WO2015171723A1
(en)
|
2014-05-06 |
2015-11-12 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
WO2015187541A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
CN112481283A
(zh)
|
2014-07-21 |
2021-03-12 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
DK3194443T3
(da)
|
2014-09-17 |
2021-09-27 |
Novartis Ag |
Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
US10143682B2
(en)
|
2014-10-28 |
2018-12-04 |
Koushi Yamaguchi |
Medicine for improving state of pregnancy, and use thereof
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN106188093B
(zh)
*
|
2015-05-08 |
2018-06-12 |
上海医药工业研究院 |
一种雷帕霉素结构类似物及其制备方法
|
WO2016185443A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
CA2997442C
(en)
|
2015-09-04 |
2021-01-26 |
Yale University |
Polymeric bile acid nanocompositions targeting the pancreas and colon
|
EP3373927A1
(en)
|
2015-11-11 |
2018-09-19 |
Novartis AG |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
JP7262100B2
(ja)
|
2016-04-29 |
2023-04-21 |
アイカーン スクール オブ メディスン アット マウント サイナイ |
長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
|
KR102565885B1
(ko)
|
2016-07-20 |
2023-08-09 |
유니버시티 오브 유타 리서치 파운데이션 |
Cd229 car t 세포 및 이의 사용 방법
|
RU2759334C2
(ru)
|
2016-09-21 |
2021-11-12 |
Нексткьюр, Инк. |
Антитела против siglec-15 и способы их применения
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
BR112019010470A2
(pt)
|
2016-11-23 |
2019-09-10 |
Novartis Ag |
métodos de realce de resposta imune com everolimo, dactolisib ou ambos
|
US20200081010A1
(en)
|
2016-12-02 |
2020-03-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
RS62456B1
(sr)
|
2016-12-22 |
2021-11-30 |
Amgen Inc |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
|
CN110603038A
(zh)
|
2017-02-10 |
2019-12-20 |
塔姆山治疗公司 |
雷帕霉素类似物
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
EP3848065B1
(en)
|
2017-05-15 |
2023-07-26 |
C. R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20190336609A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019217661A1
(en)
|
2018-05-09 |
2019-11-14 |
Yale University |
Compositions and systems for ex vivo cell modulation and methods of use thereof
|
EP3790592A1
(en)
|
2018-05-09 |
2021-03-17 |
Yale University |
Particles for spatiotemporal release of agents
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3802537A1
(en)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
JP7382353B2
(ja)
*
|
2018-06-15 |
2023-11-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
ラパマイシン類似体およびその使用
|
CN112533599A
(zh)
|
2018-08-10 |
2021-03-19 |
山口晃史 |
与母体和胎儿的关系中的体液免疫相关的疾病的治疗药
|
JP7262581B2
(ja)
|
2018-11-14 |
2023-04-21 |
ルトニックス,インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3900729A4
(en)
|
2018-12-18 |
2022-09-07 |
Koushi Yamaguchi |
AGENT FOR TREATING INFERTILITY, RECURRENT MISSORAGE AND IMPROVING PREGNANCY
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
MA54547A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
ES2953821T3
(es)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
Inhibidores de KIF18A
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
JP7061236B2
(ja)
|
2019-01-22 |
2022-04-27 |
エオビアン ファーマシューティカルズ, インコーポレイテッド |
Mtorcモジュレーターおよびその使用
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
CN113939324A
(zh)
|
2019-04-08 |
2022-01-14 |
巴德外周血管股份有限公司 |
在经改性装置表面上具有药物洗脱涂层的医疗装置
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
EP3972973A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
WO2021001743A1
(en)
|
2019-07-02 |
2021-01-07 |
Effector Therapeutics, Inc. |
Translation inhibitors and uses thereof
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
IL292438A
(en)
|
2019-10-28 |
2022-06-01 |
Merck Sharp & Dohme |
Small molecules that inhibit the g12c mutant of kras
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
CA3159559A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
EP4054719A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
PE20230249A1
(es)
|
2019-11-08 |
2023-02-07 |
Revolution Medicines Inc |
Compuestos de heteroarilo biciclicos y usos de estos
|
WO2021097212A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
CN115209897A
(zh)
*
|
2019-12-05 |
2022-10-18 |
安纳库利亚治疗公司 |
雷帕霉素类似物及其用途
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
KR20230084095A
(ko)
|
2020-03-27 |
2023-06-12 |
에오비안 파마슈티컬스, 인크. |
Mtorc1 조절제 및 이의 용도
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
CN116600789A
(zh)
|
2020-06-19 |
2023-08-15 |
耶鲁大学 |
用于诱导耐受性的聚合胆汁酸酯纳米颗粒
|
AU2021308045A1
(en)
|
2020-07-15 |
2023-02-23 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
EP4185590A2
(en)
*
|
2020-07-21 |
2023-05-31 |
Aeovian Pharmaceuticals, Inc. |
Mtorc1 modulators and uses thereof
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
KR20230067635A
(ko)
|
2020-09-15 |
2023-05-16 |
레볼루션 메디슨즈, 인크. |
암의 치료에서 ras 억제제로서 인돌 유도체
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
WO2022198101A1
(en)
|
2021-03-19 |
2022-09-22 |
Trained Therapeutix Discovery, Inc. |
Compounds for regulating trained immunity, and their methods of use
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
CR20230570A
(es)
|
2021-05-05 |
2024-01-22 |
Revolution Medicines Inc |
Inhibidores de ras
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|